Merck's Bioprocessing Production Centre in Daejeon, South Korea
New Merck bioprocessing centre expected to open late 2026.
Overview
Merck is set to establish a new Bioprocessing Production Centre in Daejeon, South Korea, with an investment of over €300 million. Announced in March 2024, the facility is expected to be operational by late 2026 and aims to bolster Merck’s presence in the Asia-Pacific region.
Key Features:
Facility Size: The centre will span 43,000m².
Products: It will supply dry powder cell culture media, process liquids, and sterile sampling systems.
Employment: Expected to create 300 jobs by 2028.
Development: Partnering with Kolon Global for construction.
Strategic Importance
This investment aligns with Merck’s strategy to expand its Life Science business and meet the growing demand for biologics in the Asia-Pacific market. The facility will support biotech firms and enhance collaborations with local research institutions and universities.
Author
BioFocus Newsroom